Background
SSCC, Head and Neck Squamous Cell Carcinoma, cancer, HNSCC, tumors
CANCER, TUMORS, SIDE EFFECT
Head and Neck Squamous Cell Carcinoma (HNSCC) are the seventh most common cancer worldwide, with approximately 600.000 new cases diagnosed each year [First, partial open laryngectomy is associated to high stable local control rate (around 77%) [Secondarily, the development of new radiation techniques (Intensity Modulated Radiotherapy, IMRT) and the concurrent administration of chemotherapy drugs allow better organ preservation and reduce tracheostomy rate [Thirdly, the development of new surgical instruments enables a Trans-oral approach with Laser Microsurgery (TLM). TLM gives a 2-year Overall Survival (OS) of 83% for pT1-T2 tumors, with a larynx preservation in 95% [Subsequently, Trans-oral Robotic Surgery (TORS) emerged as an evolution of the TLM [Actually, the current standards of treatment are based on either surgery or radiotherapy. The treatment choice is center-, tumor- and patient-dependent with different side effect profiles and technical constraints [Concerning the QoL of the patients treated for HNSCC, one prospective study has been published (“ORATOR study” [The main objective of this trial is to assess and compare objectively and prospectively the efficacy of different therapeutic approaches (radiotherapy ± chemotherapy, TLM and TORS) in SSCC patients according to 4 classes of outcomes; quality of life, oncological, functional and economic resources.